These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 31129265)

  • 21. LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson's Disease, Where Do We Stand?
    Taymans JM; Greggio E
    Curr Neuropharmacol; 2016; 14(3):214-25. PubMed ID: 26517051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).
    Deng X; Choi HG; Buhrlage SJ; Gray NS
    Expert Opin Ther Pat; 2012 Dec; 22(12):1415-26. PubMed ID: 23126385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LRRK2 in Parkinson disease: challenges of clinical trials.
    Tolosa E; Vila M; Klein C; Rascol O
    Nat Rev Neurol; 2020 Feb; 16(2):97-107. PubMed ID: 31980808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LRRK2 in Parkinson's disease: protein domains and functional insights.
    Mata IF; Wedemeyer WJ; Farrer MJ; Taylor JP; Gallo KA
    Trends Neurosci; 2006 May; 29(5):286-93. PubMed ID: 16616379
    [TBL] [Abstract][Full Text] [Related]  

  • 26. LRRK2 and Parkinson's Disease: From Lack of Structure to Gain of Function.
    Blanca Ramírez M; Madero-Perez J; Rivero-Rios P; Martinez-Salvador M; Lara Ordonez AJ; Fernandez B; Fdez E; Hilfiker S
    Curr Protein Pept Sci; 2017; 18(7):677-686. PubMed ID: 26965688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting leucine-rich repeat kinase 2 in Parkinson's disease.
    Chan SL; Angeles DC; Tan EK
    Expert Opin Ther Targets; 2013 Dec; 17(12):1471-82. PubMed ID: 24206363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemical Biology of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors.
    Estrada AA; Sweeney ZK
    J Med Chem; 2015 Sep; 58(17):6733-46. PubMed ID: 25915084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LRRK2 Phosphorylation.
    Nichols RJ
    Adv Neurobiol; 2017; 14():51-70. PubMed ID: 28353278
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Development and Design Strategy of Leucine-Rich Repeat Kinase 2 Inhibitors: Promising Therapeutic Agents for Parkinson's Disease.
    Tang X; Xing S; Ma M; Xu Z; Guan Q; Chen Y; Feng F; Liu W; Chen T; Chen Y; Sun H
    J Med Chem; 2023 Feb; 66(4):2282-2307. PubMed ID: 36758171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The c-Abl inhibitor in Parkinson disease.
    Zhou ZH; Wu YF; Wang XM; Han YZ
    Neurol Sci; 2017 Apr; 38(4):547-552. PubMed ID: 28078567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease.
    Domingos S; Duarte T; Saraiva L; Guedes RC; Moreira R
    Future Med Chem; 2019 Aug; 11(15):1953-1977. PubMed ID: 31517532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. What Have We Learned from Cerebrospinal Fluid Studies about Biomarkers for Detecting LRRK2 Parkinson's Disease Patients and Healthy Subjects with Parkinson's-Associated LRRK2 Mutations?
    Loeffler DA; Aasly JO; LeWitt PA; Coffey MP
    J Parkinsons Dis; 2019; 9(3):467-488. PubMed ID: 31322581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LRRK2 Targeting Strategies as Potential Treatment of Parkinson's Disease.
    Wojewska DN; Kortholt A
    Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease.
    Hu D; Niu JY; Xiong J; Nie SK; Zeng F; Zhang ZH
    Curr Med Sci; 2018 Dec; 38(6):1012-1017. PubMed ID: 30536063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Parkinson's disease protein LRRK2 impairs proteasome substrate clearance without affecting proteasome catalytic activity.
    Lichtenberg M; Mansilla A; Zecchini VR; Fleming A; Rubinsztein DC
    Cell Death Dis; 2011 Aug; 2(8):e196. PubMed ID: 21866175
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers.
    Vilas D; Shaw LM; Taylor P; Berg D; Brockmann K; Aasly J; Marras C; Pont-Sunyer C; Ríos J; Marek K; Tolosa E
    Mov Disord; 2016 Jun; 31(6):906-14. PubMed ID: 27041685
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons.
    Henderson MX; Peng C; Trojanowski JQ; Lee VMY
    Acta Neuropathol Commun; 2018 May; 6(1):45. PubMed ID: 29855356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fibroblast Biomarkers of Sporadic Parkinson's Disease and LRRK2 Kinase Inhibition.
    Smith GA; Jansson J; Rocha EM; Osborn T; Hallett PJ; Isacson O
    Mol Neurobiol; 2016 Oct; 53(8):5161-77. PubMed ID: 26399642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LRRK2 Phosphorylation: Behind the Scenes.
    De Wit T; Baekelandt V; Lobbestael E
    Neuroscientist; 2018 Oct; 24(5):486-500. PubMed ID: 29385885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.